On Monday, IGC Pharma Inc (AMEX: IGC) opened higher 5.34% from the last session, before settling in for the closing price of $0.36. Price fluctuations for IGC have ranged from $0.25 to $0.91 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 4.59% annually for the last half of the decade. Company’s average yearly earnings per share was noted 40.91% at the time writing. With a float of $52.67 million, this company’s outstanding shares have now reached $66.69 million.
In an organization with 67 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 44.38%, operating margin of -788.17%, and the pretax margin is -1062.47%.
IGC Pharma Inc (IGC) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of IGC Pharma Inc is 32.00%, while institutional ownership is 3.62%. The most recent insider transaction that took place on Sep 25 ’24, was worth 200,000. In this transaction Director of this company bought 588,235 shares at a rate of $0.34, taking the stock ownership to the 942,402 shares. Before that another transaction happened on Aug 12 ’24, when Company’s Director proposed sale 200,000 for $0.39, making the entire transaction worth $78,200.
IGC Pharma Inc (IGC) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 40.91% per share during the next fiscal year.
IGC Pharma Inc (AMEX: IGC) Trading Performance Indicators
Check out the current performance indicators for IGC Pharma Inc (IGC). In the past quarter, the stock posted a quick ratio of 0.91. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 24.86.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.19, a number that is poised to hit -0.03 in the next quarter and is forecasted to reach -0.12 in one year’s time.
Technical Analysis of IGC Pharma Inc (IGC)
Let’s dig in a bit further. During the last 5-days, its volume was 0.33 million. That was inferior than the volume of 0.51 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 47.95%. Additionally, its Average True Range was 0.02.
During the past 100 days, IGC Pharma Inc’s (IGC) raw stochastic average was set at 26.79%, which indicates a significant decrease from 63.38% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 49.69% in the past 14 days, which was lower than the 57.76% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.3726, while its 200-day Moving Average is $0.4157. However, in the short run, IGC Pharma Inc’s stock first resistance to watch stands at $0.3973. Second resistance stands at $0.4196. The third major resistance level sits at $0.4392. If the price goes on to break the first support level at $0.3554, it is likely to go to the next support level at $0.3358. Assuming the price breaks the second support level, the third support level stands at $0.3135.
IGC Pharma Inc (AMEX: IGC) Key Stats
There are currently 77,449K shares outstanding in the company with a market cap of 29.33 million. Presently, the company’s annual sales total 1,350 K according to its annual income of -13,000 K. Last quarter, the company’s sales amounted to 410 K and its income totaled -1,720 K.
